🇺🇸 FDA
Pipeline program

APL-2

APL2-308

Phase 3 small_molecule completed

Quick answer

APL-2 for Paroxysmal Nocturnal Hemoglobinuria is a Phase 3 program (small_molecule) at Apellis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Apellis Pharmaceuticals
Indication
Paroxysmal Nocturnal Hemoglobinuria
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials